bluuebunny/crossref_metadata_2025_split huggingface dataset:
In Situ Halide Exchange of Cesium Lead Halide Perovskites for Blue Light‐Emitting Diodes
Authors: Tong Yunfang , Bi Xiaoying , Xu Shuang , Min Hao , Cheng Lu , Kuang Zhiyuan , Yuan Lingzhi , Zhou Fuyi , Chu Ying , Xu Lei , Zhu Lin , Zhao Ni , Wang Nana , Huang Wei , Wang Jianpu 
Published: October 2022

Abstract3D perovskites are promising to achieve efficient and bright deep‐blue light‐emitting diodes (LEDs), which are required for lighting and display applications. However, the efficiency of deep‐blue 3D perovskite‐based LEDs is limited by high density of defects in perovskites, and their deep‐blue emission is not easy to achieve due to the halide phase separation and low solubility of chloride in precursor solutions. Here, an in situ halide exchange method is developed to achieve deep‐blue 3D perovskites by spin‐coating an organic halide salts solution to treat blue 3D perovskites. It is revealed that the halide‐exchange process is mainly determined by halide ion diffusion targeting a concentration equalization, which leads to homogeneous 3D mixed‐halide perovskites. By further introducing multifunctional organic ammonium halide salts into the exchange solution to passivate defects, high‐quality deep‐blue perovskites with reduced trap density can be obtained. This approach leads to efficient deep‐blue perovskite LEDs with a peak external quantum efficiency (EQE) of 4.6% and a luminance of 1680 cd m−2, which show color coordinates of (0.131, 0.055), very close to the Rec. 2020 blue standard. Moreover, the halide exchange method is bidirectional, and blue perovskite LEDs can be achieved with color coordinates of (0.095, 0.160), exhibiting a high EQE of 11.3%.
Multiscale Reciprocal Space Mapping of Magnetite Mesocrystals
Authors: Chumakova Aleksandra , Steegemans Tristan , Baburin Igor A. , Mistonov Alexander , Dubitskiy Ilya S. , Schlotheuber Julian , Kirner Felizitas , Sturm Sebastian , Lubk Axel , Müller‐Caspary Knut , Wimmer Ilona , Fonin Mikhail , Sturm Elena V. , Bosak Alexeï 
Published: October 2022

AbstractMesocrystals are a class of nanostructured material, where a multiple‐length‐scale structure is a prerequisite of many interesting phenomena. Resolving the mesocrystal structure is quite challenging due to their structuration on different length scales. The combination of small‐ and wide‐angle X‐ray scattering (SAXS and WAXS) techniques offers the possibility of non‐destructively probing mesocrystalline structures simultaneously, over multiple length scales to reveal their microscopic structure. This work describes how high dynamical range of modern detectors sheds light on the weak features of scattering, significantly increasing the information content. The detailed analysis of X‐ray diffraction (XRD) from the magnetite mesocrystals with different particle sizes and shapes is described, in tandem with electron microscopy. The revealed features provide valuable input to the models of mesocrystal growth and the choice of structural motif; the impact on magnetic properties is discussed.
Tailored Polypeptide Star Copolymers for 3D Printing of Bacterial Composites Via Direct Ink Writing
Authors: Murphy Robert D. , Garcia Ronnie V. , Oh Seung J. , Wood Tanner J. , Jo Kyoo D. , Read de Alaniz Javier , Perkins Ed , Hawker Craig J. 
Published: October 2022

AbstractHydrogels hold much promise for 3D printing of functional living materials; however, challenges remain in tailoring mechanical robustness as well as biological performance. In addressing this challenge, the modular synthesis of functional hydrogels from 3‐arm diblock copolypeptide stars composed of an inner poly(l‐glutamate) domain and outer poly(l‐tyrosine) or poly(l‐valine) blocks is described. Physical crosslinking due to ß‐sheet assembly of these star block copolymers gives mechanical stability during extrusion printing and the selective incorporation of methacrylate units allows for subsequent photocrosslinking to occur under biocompatible conditions. This permits direct ink writing (DIW) printing of bacteria‐based mixtures leading to 3D objects with high fidelity and excellent bacterial viability. The tunable stiffness of different copolypeptide networks enables control over proliferation and colony formation for embedded Escherichia coli bacteria as demonstrated via isopropyl ß‐d‐1‐thiogalactopyranoside (IPTG) induction of green fluorescent protein (GFP) expression. This translation of molecular structure to network properties highlights the versatility of these polypeptide hydrogel systems with the combination of writable structures and biological activity illustrating the future potential of these 3D‐printed biocomposites.
Synthesis of a bio‐based plasticizer from vanillic acid and its effects on poly(vinyl chloride)
Authors: Zhu Huichao , Yang Jianjun , Wu Mingyuan , Wu Qingyun , Liu Jiuyi , Zhang Jianan 
Published: October 2022

AbstractA new bio‐based plasticizer, VA8‐8, was prepared derived from vanillic acid, and its structure was verified by nuclear magnetic resonance. It was incorporated into poly(vinyl chloride) (PVC) to replace dioctyl phthalate (DOP), and its plasticizing performance was evaluated. The results indicated that VA8‐8 shows good compatible with PVC resin, and has a excellent plasticizing effect for PVC. When DOP was partially or completely substituted with VA8‐8, the Tg value PVC blends dropped from 34.6 to 24.3°C and the elongation at break increased from 196.4% to 301.9%, suggesting the enhanced plasticizing efficiency of plasticizer. The plasticizing mechanism was also simulated, and the interactions between VA8‐8 and PVC molecules were discussed. The thermogravimetric analysis showed VA8‐8 can more effectively improve the thermal stability of PVC than DOP. In addition, the migration resistance of VA8‐8 was generally superior to that of DOP. Therefore, VA8‐8 is a comparable to or better plasticizer than DOP, and it is a promising alternative plasticizer for PVC.
Ludwig Heinrich Bojanus and the anatomy of the European pond turtle: Facts, fiction, and future
Authors: Lambertz Markus 
Published: October 2022

AbstractDetailed anatomical knowledge is a prerequisite for studying a variety of biological questions. This holds true particularly for the evolutionary realm, in which fossils play an important role. Putting paleontological data in perspective consequently requires a profound knowledge of the corresponding structures of the extant representatives of a given lineage as well. Numerous morphological studies have contributed to our understanding of chelonian anatomy over the past centuries, but one of the earliest ones—whose completion celebrated its bicentenary with this symposium—still stands out among all of them: Anatome Testudinis Europaeae, published by Ludwig Heinrich Bojanus (1776–1827) in two installments in 1819 and 1821. Numerous myths around this publication have evolved ever since. The intent of this article is to set the record straight for some of them, and, based on personal inspection of multiple copies, to discuss currently unrecognized aspects about the existence of exceptional colored variant editions. This ends in a proposal for how this work could be used even more effectively in its upcoming third century of existence. Last but not least and despite the controversies related to its bibliographical aspects, one fact remains an unchallenged reality: Anatome Testudinis Europaeae, even 200 years after its first publication, still ranks very high among the most detailed and accurate anatomical works on a single chelonian—and for that matter reptilian—species ever produced and has lost absolutely none of its value for modern‐day science.
COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2
Authors: Shah Syed Muhammad Ismail , Yasmin Farah , Memon Roha Saeed , Jatoi Nadia Nazir , Savul Ilma Saleh , Kazmi Sana , Monawwer Syed Abdullah , Zafar Muhammad Daim Bin , Asghar Muhammad Sohaib , Tahir Muhammad Junaid , Lee Ka Yiu 
Published: October 2022

AbstractIntroductionThis review highlights the potential mechanisms of neuromuscular manifestation of COVID‐19, especially myasthenia gravis (MG).MethodsAn extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020.ResultsExacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID‐19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders.ConclusionsFurther clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID‐19 can pre‐existent subclinically or develop as a new‐onset disease.
Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders
Authors: Li Jinghong , He Yan , Wang Honghao , Chen Jinyu 
Published: October 2022

AbstractAimThe aims of this pilot study were to investigate the levels of biomarkers of microglial/macrophage activation—YKL‐40, sCD163, and sCD14—in patients with neuromyelitis optica spectrum disorder (NMOSD) and determine the possible associations between these biomarkers and Expanded Disability Status Scale (EDSS) scores.MethodsWe measured the levels of three microglia‐/macrophage‐related proteins (YKL‐40, soluble CD163, and soluble CD14) in cerebrospinal fluid (CSF) using enzyme‐linked immunosorbent assays. In addition, patients’ neurological disability levels were assessed using EDSS scores.ResultsNMOSD patients had significantly higher CSF levels of YKL‐40(210.52 ± 161.62 for NMOSD and 63.18 ± 9.22 for control), sCD163 (87.23 ± 56.85 for NMOSD and 58.14 ± 7.66 for control), and sCD14 (68.22 ± 24.11 for NMOSD and 55.75 ± 9.48 for control) compared with controls. Furthermore, these biomarker levels were positively correlated with EDSS scores in patients with NMOSD (r = 0.303, p = .002 for YKL‐40; r = 0310, p = .001 for sCD14; r = 0.250, p = .011 for sCD163), but not in patients with multiple sclerosis or glial fibrillary acidic protein astrocytopathy.ConclusionOur findings suggest that microglial/macrophage activation may be implicated in the pathogenesis of NMOSD.
Weighted correlation network analysis identifies multiple susceptibility loci for low‐grade glioma
Authors: Niu Xiaodong , Pan Qi , Zhang Qianwen , Wang Xiang , Liu Yanhui , Li Yu , Zhang Yuekang , Yang Yuan , Mao Qing 
Published: October 2022

AbstractBackgroundThe current molecular classifications cannot completely explain the polarized malignant biological behavior of low‐grade gliomas (LGGs), especially for tumor recurrence. Therefore, we tried to identify suspicious hub genes related to tumor recurrence in LGGs.MethodsIn this study, we constructed a gene‐miRNA‐lncRNA co‐expression network for LGGs by a weighted gene co‐expression network analysis (WGCNA). GDCRNATools and the WGCNA R package were mainly used in data analysis.ResultsSequencing data from 502 LGG patients were analyzed in this study. Compared with recurrent glioma tissues, we identified 774 differentially expressed (DE) mRNAs, 49 DE miRNAs, and 129 DE lncRNAs in primary LGGs and ultimately determined that the expression of MKLN1 was related to tumor recurrence in LGG.ConclusionThis study identified the potential biomarkers for the pathogenesis and recurrence of LGGs and proposed that MKLN1 could be a potential therapeutic target.
hsa‐mir‐133a‐2 promotes the proliferation and invasion of cervical cancer cells by targeting the LAMB3‐mediated PI3K/ATK pathway
Authors: Sui Xiaoyu , Sun Yurong , Zhang Guiyu , Chi Na , Guan Yitong , Wang Dan , Li Xiulan 
Published: October 2022

AbstractObjectiveCervical cancer, one of the common types of malignant tumors progressed in women, is on the rise in developing countries. Numerous previous studies have demonstrated that hsa‐mir‐133a‐2 miRNA is abnormally expressed in cervical cancer cells. However, its fundamental mechanism in cervical cancer needs to be further clarified. Our study set out to investigate the effect of hsa‐mir‐133a‐2 on the phenotypes of cervical cancer cells as well as any potential molecular processes involved in the proliferation and invasion of cervical cancer cells.MethodsThe Cancer Genome Atlas‐cervical squamous cell carcinoma and endocervical adenocarcinoma(TCGA‐CESC) was adopted in order to verify the expression of hsa‐mir‐133a‐2 in cervical cancer tissues and to identify its potential targets. The interaction between Laminin subunit beta‐3(LAMB3) and hsa‐mir‐133a‐2 was verified by TargetScan database as well as Luciferase reporter assay. The Cell Counting Kit‐8 (CCK8) and transwell methods were utilized to assess the influence of hsa‐mir‐133a‐2 on the proliferation and invasion characteristics of cervical cancer cells. We studied the role that hsa‐mir‐133a‐2 plays in cervical cancer progression through Kyoto Encyclopedia of Genes and Genomes(KEGG) analysis as well as Western Blot (WB) experiment.ResultsDown‐regulation of hsa‐mir‐133a‐2 was detected in cervical cancer tissues. It directly targeted LAMB3 and negatively regulated LAMB3 expression. The overexpression of hsa‐mir‐133a‐2 has a significant inhibiting effect on cervical cancer cell proliferation and invasion. The overexpression of hsa‐mir‐133a‐2 significantly inhibits the proliferation and invasion of cervical cancer cells. Moreover, the LAMB3 was able to up‐regulate the phosphorylation levels of AKT and phosphatidylinositol 3‐kinase (PI3K) protein in cervical cancer cells. hsa‐mir‐133a‐2 could also modulate the PI3K/AKT signaling pathway by targeting LAMB3.Conclusionhsa‐mir‐133a‐2 inhibits cervical cancer cell proliferation and invasion by indirectly regulating the PI3K/AKT signaling pathway, providing us with a new clinical treatment strategy for cervical cancer.
Early Termination of Oncology Clinical Trials in the United States
Authors: Zhang Ellen , DuBois Steven G. 
Published: October 2022

AbstractPurposeThe aim of this study was to evaluate the rate of early trial discontinuation of oncology trials and reasons for early termination, to assess potential trends in rates of oncology trial termination, and to perform a comprehensive analysis of predictors of early termination. This study intends to inform efforts in improving efficiency of the oncology clinical trial enterprise.MethodsWe conducted a cross‐sectional study of interventional cancer clinical trials registered in ClinicalTrials.gov database from September 27, 2007 to June 30, 2015, with at least one site listed in the United States. We evaluated predictors of early trial termination using Fisher exact or χ2 tests and logistic regression.ResultsOf 8687 trials, 22.74% (n = 1975) were terminated trials. Rates of early trial termination appeared stable over the study. Statistically significant univariate predictors of early termination for any reason include cancer category, phase, funding source, location, and age. In multivariable analysis, trials spanning multiple cancer categories and international trials were less likely to terminate early whereas phase 2 trials and trials funded by academia/foundation were more likely to terminate early. The most common reason for early termination was “Other, Multiple Reasons, or Unknown” (36.9%), followed by accrual issues (34.5%). In multivariate analysis among all terminated trials, supportive care trials, phase 2 trials, and non‐industry funded trials had significantly higher odds of trial discontinuation specifically due to poor accrual.ConclusionIn this national sample of cancer clinical trials, early trial discontinuation was common. Many factors influenced early trial termination with poor accrual being a common reason. Specific trial features are associated with differential likelihood of early trial termination for any reason and for early trial termination due to poor accrual.
BDP1 as a biomarker in serous ovarian cancer
Authors: Cabarcas‐Petroski Stephanie , Olshefsky Gabriella , Schramm Laura 
Published: October 2022

AbstractBackgroundTFIIIB, an RNA polymerase III specific transcription factor has been found to be deregulated in human cancers with much of the research focused on the TBP, BRF1, and BRF2 subunits. To date, the TFIIIB specific subunit BDP1 has not been investigated in ovarian cancer but has previously been shown to be deregulated in neuroblastoma, breast cancer, and Non‐Hodgkins lymphoma.ResultsUsing in silico analysis of clinically derived platforms, we report a decreased BDP1 expression as a result of deletion in serous ovarian cancer and a correlation with higher and advanced ovarian stages. Further analysis in the context of TP53 mutations, a major contributor to ovarian tumorigenesis, suggests that high BDP1 expression is unfavorable for overall survival and high BDP1 expression occurs in stages 2, 3 and 4 serous ovarian cancer. Additionally, high BDP1 expression is disadvantageous and unfavorable for progression‐free survival. Lastly, BDP1 expression significantly decreased in patients treated with first‐line chemotherapy, platin and taxane, at twelve‐month relapse‐free survival.ConclusionsTaken together with a ROC analysis, the data suggest BDP1 could be of clinical relevance as a predictive biomarker in serous ovarian cancer. Lastly, this study further demonstrates that both the over‐ and under expression of BDP1 warrants further investigation and suggests BDP1 may exhibit dual function in the context of tumorigenesis.
Gonadotropin‐releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study
Authors: Chou Yi‐Sheng , Wang Chun‐Chieh , Hsu Li‐Fei , Chuang Pei‐Hung , Cheng Chi‐Feng , Li Nai‐Hsin , Chen Chu‐Chieh , Chen Chien‐Liang , Lai Yun‐Ju , Yen Yung‐Feng 
Published: October 2022

AbstractBackgroundThe risk of ischemic heart disease (IHD) due to the impact of gonadotropin‐releasing hormone (GnRH) agonists among female patients with breast cancer remains a controversy.MethodsInformation from the Registry for Catastrophic Illness, the National Health Insurance Research Database (NHIRD), and the Death Registry Database in Taiwan were analyzed. Female patients with breast cancer were selected from the Registry for Catastrophic Illness from January 1, 2000, to December 31, 2018. All the breast cancer patients were followed until new‐onset IHD diagnosis, death, or December 31, 2018. A Kaplan–Meier survival curve was drawn to show the difference between patients treated with and without GnRH agonists. The Cox regression analysis was used to investigate the effects of GnRH agonists and the incidence of IHD.ResultsA total of 172,850 female patients with breast cancer were recognized with a mean age of 52.6 years. Among them, 6071(3.5%) had received GnRH agonist therapy. Kaplan–Meier survival curves showed a significant difference between patients with and without GnRH therapy (log‐rank p < 0.0001). Patients who received GnRH therapy had a significantly decreased risk of developing IHD than those without GnRH therapy (HR = 0.18; 95% CI = 0.14–0.23). After adjusting for age, treatment, and comorbidity, patients who received GnRH therapy still had a significantly lower risk of developing IHD (AHR = 0.5, 95% CI = 0.39–0.64).ConclusionThe study showed that the use of GnRH agonists for breast cancer treatment was significantly associated with a reduced risk of IHD. Further research is required to investigate the possible protective effect of GnRH on IHD.
Synthesis and Structure‐Activity Relationship Studies of Novel Aryl Sulfonamides and Their Activity against Human Breast Cancer Cell Lines
Authors: Azevedo‐Barbosa Helloana , Ferreira‐Silva Guilherme Álvaro , do Vale Bianca Pereira , Hawkes Jamie Anthony , Ionta Marisa , Carvalho Diogo Teixeira 
Published: October 2022

AbstractA series of structural analogs of aryl sulfonamide hybrid compounds were synthesised and their cytotoxic activity was evaluated against three human breast cancer cell lines (MCF‐7, MDA‐MB‐231 and Hs 578T). The compounds were designed through electronic, hydrophobic and steric modifications using the chemical structure of N‐{4‐[(2‐hydroxy‐3‐methoxy‐5‐propylphenyl)sulfamoyl]phenyl}acetamide (referred to as compound 7) as a starting point to then assess a structure‐activity relationship (SAR) study. From the data generated, we observed that compounds 9, 10 and 11 (which have modifications in the substituents of the aryl sulfonamide), efficiently reduced the cell viability of MCF‐7 and MDA‐MB‐231 cell cultures. Based on initial data, we selected compounds 10 and 11 for further investigations into their antiproliferative and/or cytotoxic profile against MDA‐MB‐231 cells, and we noted that compound 10 was the most promising compound in the series. Compound 10 promoted morphological changes and altered the dynamics of cell cycle progression in MDA‐MB‐231 cells, inducing arrest in G1/S transition. Taken together, these results show that the dihydroeugenol‐aryl‐sulfonamide hybrid compound 10 (which has an electron withdrawing nitro group) displays promising antiproliferative activity against MDA‐MB‐231 cell lines.
Evaluation of Potential Racial Disparities inCYP2C19‐Guided P2Y12Inhibitor Prescribing After Percutaneous Coronary Intervention
Authors: Cavallari Larisa H. , Limdi Nita A. , Beitelshees Amber L. , Lee James C. , Duarte Julio D. , Franchi Francesco , Tuteja Sony , Giri Jay , Empey Philip E. , Kreutz Rolf P. , Skaar Todd C. , Allen John M. , Coons James C. , Gong Yan , McDonough Caitrin W. , Stevenson James M. , Thomas Cameron D. , Johnson Julie A. , Stouffer George A. , Angiolillo Dominick J. , Lee Craig R. ,   the IGNITE Network
Published: October 2022

Black patients suffer worse outcomes after percutaneous coronary intervention (PCI) than White patients. Inequities in antiplatelet prescribing may contribute to this health disparity. We compared P2Y12inhibitor prescribing by race followingCYP2C19genotyping to guide antiplatelet therapy selection after PCI. Patients from 9 sites that performed clinicalCYP2C19genotyping after PCI were included. Alternative therapy (e.g., prasugrel or ticagrelor) was recommended forCYP2C19no‐function allele carriers, in whom clopidogrel is predicted to be less effective. The primary outcome was choice of P2Y12inhibitor (clopidogrel vs. alternative therapy) based on genotype. Of 3,342 patients included, 2,448 (73%) were White, and 659 (20%) were Black. More Black than White patients had a no‐function allele (34.3% vs. 29.7%,P = 0.024). At hospital discharge following PCI, 44.2% of Black and 44.0% of White no‐function allele carriers were prescribed alternative therapy. At the time of the last follow‐up within 12 months, numerically fewer Black (51.8%) than White (56.7%) no‐function allele carriers were prescribed alternative therapy (P = 0.190). However, the difference was not significant after accounting for other factors associated with P2Y12inhibitor selection (odds ratio 0.79, 95% confidence interval 0.58–1.08). Alternative therapy use did not differ between Black (14.3%) and White (16.7%) patients without a no‐function allele (P = 0.232). Among real‐world patients who receivedCYP2C19testing after PCI, P2Y12inhibitor prescribing rates did not differ between Black and White patients. Our data suggest an absence of racial disparity in genotype‐guided antiplatelet prescribing among patients receivingCYP2C19testing.